Horizon Discovery, a life science spin-out of Cambridge University, signs its second collaboration with pharmaceutical firm AstraZeneca.
Horizon Discovery has partnered with AstraZeneca to explore a range of oncology-relevant genotypes, marking its second collaboration with the pharmaceutical firm.
The deal is worth up to $88m in milestone payments to the Cambridge University spin-out, which will also receive an undisclosed payment up front.
The announcement builds on a strong 2013 for the company, which won the Licencing Deal of the Year at the 2013 SCRIP Intelligence Awards for its first collaboration with AstraZeneca and also closed a
